Download PDF
Semin Respir Crit Care Med 2004; 25(3): 271-281
DOI: 10.1055/s-2004-829500
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Leprosy of the Past and Today

John M. Grange1 , Julie I. Lethaby2
  • 1Centre for Infectious Diseases and International Health, Royal Free and University College Medical School, Windeyer Institute for Medical Sciences, London, United Kingdom
  • 2The Leprosy Mission, England, Wales, the Channel Islands and the Isle of Man, Cambridge, United Kingdom
Further Information

Publication History

Publication Date:
29 June 2004 (online)

    Permissions and Reprints

Despite enhanced disease control efforts, leprosy remains an important cause of disability in several countries. Being based on case detection, the exact prevalence of the disease is not easily estimated. Currently around 600,000 new cases are treated annually. Advances in immunology and molecular biology have led to a greater understanding of the disease and to hopes for improved diagnostic tests and vaccination strategies. The major advance, though, is the development of highly effective combination drug regimens which, provided all doses are taken, rarely fails to cure. The challenge to leprosy control services is to overcome the stigma associated with the disease so that patients present with minimal lesions and before disabilities have developed. Although it is hoped that leprosy as a serious public health problem will be eliminated within a few years, continuing care for those suffering from deformity and rejection by society will be required for several decades.

KEYWORDS

Leprosy - Mycobacterium leprae - hypersensitivity reactions - multi-drug therapy - vaccination - stigma

REFERENCES

  • 1 Grange J M. Lupus and lepros.  Int J Lepr Other Mycobact Dis. 1988;  56 111-112
    PubMedGoogle Scholar
  • 2 Robertson J O. International Leprosy Association global project on the history of leprosy. Editorial.  Lepr Rev. 2003;  74 103-111
    PubMedGoogle Scholar
  • 3 World Health Organization .Global Strategy for the Elimination of Leprosy as a Public Health Problem. Geneva; World Health Organization 1999
    Google Scholar
  • 4 World Health Organization .Chemotherapy of Leprosy for Control Programmes. Report of a WHO Study Group, TRS 675. Geneva; World Health Organization 1982
    Google Scholar
  • 5 Cole S T, Eiglmeier K, Parkhill J et al.. Massive gene decay in the leprosy bacillus.  Nature. 2001;  409 1007-1011
    CrossrefPubMedGoogle Scholar
  • 6 Young D, Robertson B. Genomics: leprosy: a degenerative disease of the genome.  Curr Biol. 2001;  11 R381-R383
    CrossrefPubMedGoogle Scholar
  • 7 Brennan P J, Vissa V D. Genomic evidence for the retention of the essential mycobacterial cell wall in the otherwise defective Mycobacterium leprae .  Lepr Rev. 2001;  72 415-428
    PubMedGoogle Scholar
  • 8 Sassetti C M, Boyd D H, Rubin E J. Genes required for mycobacterial growth defined by high density mutagenesis.  Mol Microbiol. 2003;  48 77-84
    CrossrefPubMedGoogle Scholar
  • 9 Stanford J L, Rook G AW, Convit J et al.. Preliminary taxonomic studies on the leprosy bacillus.  Br J Exp Pathol. 1975;  56 579-585
    PubMedGoogle Scholar
  • 10 Chakrabarty A N, Dastidar S G. Is soil an alternative source of leprosy infection?.  Acta Leprol. 2001-2002;  12 79-84
    PubMedGoogle Scholar
  • 11 Grange J M, Dewar C A, Rowbotham T J. Microbe-dependence of Mycobacterium leprae: a possible intracellular relationship with protozoa.  Int J Lepr Other Mycobact Dis. 1987;  55 565
    PubMedGoogle Scholar
  • 12 Kazda J, Irgens L M, Muller K. Isolation of noncultivable acid-fast bacilli in sphagnum moss vegetation by footpad technique in mice.  Int J Lepr Other Mycobact Dis. 1980;  48 1-6
    PubMedGoogle Scholar
  • 13 Mendum T A, Chilima B Z, Hirsch P R. The PCR amplification of nontuberculous mycobacterial 16S rRNA sequences from soil.  FEMS Microbiol Lett. 2000;  185 189-192
    CrossrefPubMedGoogle Scholar
  • 14 Valverde C R, Canfield D, Tarara R, Esteves M I, Gormus B J. Spontaneous leprosy in a wild-caught cynomolgus macaque.  Int J Lepr Other Mycobact Dis. 1998;  66 140-148
    PubMedGoogle Scholar
  • 15 Paige C F, Scholl D T, Truman R W. Prevalence and incidence density of Mycobacterium leprae and Trypanosoma cruzi infections within a population of wild nine-banded armadillos.  Am J Trop Med Hyg. 2002;  67 528-532
    PubMedGoogle Scholar
  • 16 Lumpkin L R, Cox G F, Wolf J E. Leprosy in five armadillo handlers.  J Am Acad Dermatol. 1983;  9 899-903
    PubMedGoogle Scholar
  • 17 Davey T F, Rees R JW. The nasal discharge in leprosy: clinical and bacteriological aspects.  Lepr Rev. 1974;  45 121-134
    PubMedGoogle Scholar
  • 18 Sehgal V N. Leprosy following mechanical trauma.  Lepr Rev. 1986;  57 74-76
    PubMedGoogle Scholar
  • 19 Blake L A, West B C, Lary C H, Todd IV J R. Environmental nonhuman sources of leprosy.  Rev Infect Dis. 1987;  9 562-577
    PubMedGoogle Scholar
  • 20 World Health Organization . Leprosy: global situation.  Wkly Epidemiol Rec. 2000;  75 226-231
    PubMedGoogle Scholar
  • 21 World Health Organization .Leprosy. Fact Sheet No. 101. Revised January 2003 Geneva; World Health Organization 2003
    Google Scholar
  • 22 Leprosy Group, WHO .Leprosy. In: Cook GC, Zumla A Manson's Tropical Diseases. 21st ed. Edinburgh; Saunders (Elsevier) 2003: 1065-1084
    Google Scholar
  • 23 Lockwood D NJ. Leprosy (Hansen's disease). In: Warrell DA, Cox TM, Firth JD, Benz EJ Oxford Textbook of Medicine. 4th ed. Oxford; Oxford University Press 2003: 575-584
    Google Scholar
  • 24 Narayan N P, Ramu G, Desikan K V, Vallishayee R S. Correlation of clinical, histological and immunological features across the leprosy spectrum.  Indian J Lepr. 2001;  73 329-342
    PubMedGoogle Scholar
  • 25 Brennan P J. Skin test development in leprosy: progress with first-generation skin test antigens, and an approach to the second generation.  Lepr Rev. 2000;  71(suppl) S50-S54
    PubMedGoogle Scholar
  • 26 Torres P, Camarena J J, Gomez J R et al.. Comparison of PCR mediated amplification of DNA and the classical methods for detection of Mycobacterium leprae in different types of clinical samples in leprosy patients and contacts.  Lepr Rev. 2003;  74 18-30
    PubMedGoogle Scholar
  • 27 Kang T J, Kim S K, Lee S B, Chae G T, Kim J P. Comparison of two different PCR amplification products (the 18-kDa protein gene vs. RLEP repetitive sequence) in the diagnosis of Mycobacterium leprae .  Clin Exp Dermatol. 2003;  28 420-424
    CrossrefPubMedGoogle Scholar
  • 28 Chae G T, Kim M J, Kang T J et al.. DNA-PCR and RT-PCR for the 18-kDa gene of Mycobacterium leprae to assess the efficacy of multi-drug therapy for leprosy.  J Med Microbiol. 2002;  51 417-422
    PubMedGoogle Scholar
  • 29 Ridley D S, Jopling W H. Classification of leprosy according to immunity: a five-group system.  Int J Lepr Other Mycobact Dis. 1966;  34 255-273
    PubMedGoogle Scholar
  • 30 Godal M B, Myrvang B, Stanford J L, Samuel D R. Recent advances in the immunology of leprosy with special reference to new approaches in immunoprophylaxis.  Bull Inst Pasteur. 1974;  72 273-310
    PubMedGoogle Scholar
  • 31 Waters M F, Stanford J L. Giant reactions to tuberculin in lepromatous leprosy patients.  Int J Lepr Other Mycobact Dis. 1985;  53 546-553
    PubMedGoogle Scholar
  • 32 Sampaio E P, Duppre N C, Nery J A, Moreira A L, Sarno E N. Development of giant reaction in response to PPD skin test in lepromatous leprosy patients.  Int J Lepr Other Mycobact Dis. 1993;  61 205-213
    PubMedGoogle Scholar
  • 33 Bloom B R, Salgame P, Diamond B. Revisiting and revising suppressor T cells.  Immunol Today. 1992;  13 131-136
    CrossrefPubMedGoogle Scholar
  • 34 Hashimoto K, Maeda Y, Kimura H et al.. Mycobacterium leprae infection in monocyte-derived dendritic cells and its influence on antigen-presenting function.  Infect Immun. 2002;  70 5167-5176
    CrossrefPubMedGoogle Scholar
  • 35 Bloom B R. Learning from leprosy: a perspective on immunology and the third world (American Association of Immunologists Presidential Address).  J Immunol. 1986;  137 i-x
    PubMedGoogle Scholar
  • 36 Modlin R L, Hofman F M, Taylor C R, Rea T H. T-lymphocyte subsets in the skin lesions of patients with leprosy.  J Am Acad Dermatol. 1983;  8 182-189
    PubMedGoogle Scholar
  • 37 Yamamura M, Uyemura K, Deans R J et al.. Defining protective responses to pathogens: cytokine profiles in leprosy patients.  Science. 1991;  254 277-279
    PubMedGoogle Scholar
  • 38 Rook G AW, Zumla A. Advances in the immunopathogenesis of pulmonary tuberculosis.  Curr Opin Pulm Med. 2001;  7 116-123
    CrossrefPubMedGoogle Scholar
  • 39 Stanford J L, Stanford C A, Grange J M. Environmental echoes.  Sci Prog. 2001;  84(pt 2) 105-124
    PubMedGoogle Scholar
  • 40 Muzur A, Skrobonja A, Rotschild V, Skrobonja Jr A. Saints protectors from leprosy: historical hints of suggestive therapy?.  Int J Lepr Other Mycobact Dis. 2002;  70 269-273
    PubMedGoogle Scholar
  • 41 Stanford J L. The history and future of vaccination and immunotherapy for leprosy.  Trop Geogr Med. 1994;  46 93-107
    PubMedGoogle Scholar
  • 42 Samuel N M, Grange J M, Samuel S et al.. A study of the effects of intradermal administration of recombinant gamma interferon in lepromatous leprosy patients.  Lepr Rev. 1987;  58 389-400
    PubMedGoogle Scholar
  • 43 Nath I, Vemuri N, Reddi A L et al.. The effect of antigen presenting cells on the cytokine profiles of stable and reactional lepromatous leprosy patients.  Immunol Lett. 2000;  75 69-76
    CrossrefPubMedGoogle Scholar
  • 44 Filley E, Andreoli A, Steele J et al.. A transient rise in agalactosyl IgG correlating with free interleukin-2 receptors during episodes of erythema nodosum leprosum.  Clin Exp Immunol. 1989;  76 343-347
    PubMedGoogle Scholar
  • 45 Spierings E, de Boer T, Wieles B et al.. Mycobacterium leprae-specific, HLA Class II-restricted killing of human schwann cells by CD4+ Th1 cells: a novel immunopathogenic mechanism of nerve damage in leprosy.  J Immunol. 2001;  166 5883-5888
    PubMedGoogle Scholar
  • 46 Oliveira R B, Ochoa M T, Sieling P A et al.. Expression of Toll-like receptor 2 on human Schwann cells: a mechanism of nerve damage in leprosy.  Infect Immun. 2003;  71 1427-1433
    CrossrefPubMedGoogle Scholar
  • 47 Kang T J, Chae G T. Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients.  FEMS Immunol Med Microbiol. 2001;  31 53-58
    CrossrefPubMedGoogle Scholar
  • 48 Abbot N C, Beck J S, Samson P D, Butlin C R, Bennett P J, Grange J M. Cold fingers in leprosy.  Int J Lepr Other Mycobact Dis. 1992;  60 580-586
    PubMedGoogle Scholar
  • 49 Abbot N C, Beck J S, Samson P D et al.. Impairment of fingertip vasomotor reflexes in leprosy patients and apparently healthy contacts.  Int J Lepr Other Mycobact Dis. 1991;  59 537-547
    PubMedGoogle Scholar
  • 50 Abbot N C, Beck J S, Feval F et al.. Immunotherapy with Mycobacterium vaccae and peripheral blood flow in long-treated leprosy patients, a randomised, placebo-controlled trial.  Eur J Vasc Endovasc Surg. 2002;  24 202-208
    CrossrefPubMedGoogle Scholar
  • 51 Courtright P, Daniel E, Sundarrao et al.. Eye disease in multibacillary leprosy patients at the time of their leprosy diagnosis: findings from the Longitudinal Study of Ocular Leprosy (LOSOL) in India, the Philippines and Ethiopia.  Lepr Rev. 2002;  73 225-238
    PubMedGoogle Scholar
  • 52 Ridley D S. Pathogenesis of Leprosy and Related Diseases. London; Wright 1988: 89
    Google Scholar
  • 53 Nakayama E E, Ura S, Fleury R N, Soares V. Renal lesions in leprosy: a retrospective study of 199 autopsies.  Am J Kidney Dis. 2001;  38 26-30
    PubMedGoogle Scholar
  • 54 Eastwood J B, Dilley S A, Grange J M. Tuberculosis, leprosy and other mycobacterial diseases. In: Cattel W Infections of the Kidney and Urinary Tract. Oxford; Oxford University Press 1996: 291-318
    Google Scholar
  • 55 Saporta L, Yuksel A. Androgenic status in patients with lepromatous leprosy.  Br J Urol. 1994;  74 221-224
    PubMedGoogle Scholar
  • 56 Ishikawa S, Mizushima M, Furuta M, Ishikawa A, Kawamura K. Leydig cell hyperplasia and the maintenance of bone volume: bone histomorphometry and testicular histopathology in 29 male leprosy autopsy cases.  Int J Lepr Other Mycobact Dis. 2000;  68 258-266
    PubMedGoogle Scholar
  • 57 Neena K, Ammini A C, Singh M, Pandhi R K. Ovarian function in female patients with multibacillary leprosy.  Int J Lepr Other Mycobact Dis. 2003;  71 101-105
    CrossrefPubMedGoogle Scholar
  • 58 Lienhardt C, Kamate B, Jamet P et al.. Effect of HIV infection on leprosy: a three-year survey in Bamako, Mali.  Int J Lepr Other Mycobact Dis. 1996;  64 383-391
    PubMedGoogle Scholar
  • 59 Lucas S. Human immunodeficiency virus and leprosy.  Lepr Rev. 1993;  64 97-103
    PubMedGoogle Scholar
  • 60 Lawn S D, Wood C, Lockwood D N. Borderline tuberculoid leprosy: an immune reconstitution phenomenon in a human immunodeficiency virus-infected person.  Clin Infect Dis. 2003;  36 e5-e6
    CrossrefPubMedGoogle Scholar
  • 61 Brown J AK, Stone M M, Sutherland I. BCG vaccination of children against leprosy in Uganda: first results.  BMJ. 1966;  1 7-14
    PubMedGoogle Scholar
  • 62 Gupte M D. Vaccine trials in leprosy: Venezuela, Malawi and India.  Int J Lepr Other Mycobact Dis. 1999;  67(suppl 4) S32-S37
    PubMedGoogle Scholar
  • 63 Gupte M D, Vallishayee R S, Anantharaman D S et al.. Comparative leprosy vaccine trial in south India.  Indian J Lepr. 1998;  70 369-388
    PubMedGoogle Scholar
  • 64 Azuly R D. Antileprosy vaccinations.  An Bras Dermatol. 2002;  77 489-494
    PubMedGoogle Scholar
  • 65 Ramu G, Grange J M, Stanford J L. Evaluation of adjunct immunotherapy with killed Mycobacterium vaccae in the treatment of multibacillary leprosy and erythema nodosum leprosum. In: Casal M Clinical Mycobacteriology. Barcelona; Prous Science 1998: 393-402
    Google Scholar
  • 66 World Health Organization .Expert Committee on Leprosy. WHO Technical Report series, No. 874. Geneva; World Health Organization 1998
    Google Scholar
  • 67 World Health Organization .7th WHO Expert Committee on leprosy June 1997. Geneva; World Health Organization 1997
    Google Scholar
  • 68 Lockwood D, Marlowe S. Leprosy. In: Finch RG, Greenwood D, Norrby SR, Whitley RJ Antibiotic and Chemotherapy. 8th ed. Edinburgh; Churchill Livingstone 2003: 808-816
    Google Scholar
  • 69 Withington S G, Joha S, Baird D, Brink M, Brink J. Assessing socioeconomic factors in relation to stigmatisation, impairment status, and selection for socioeconomic rehabilitation: a 1-year cohort of new leprosy cases in north Bangladesh.  Lepr Rev. 2003;  74 120-123
    PubMedGoogle Scholar
  • 70 de Stigter D H, de Geus L, Heynders M L. Leprosy: between acceptance and segregation: community behavior towards persons affected by leprosy in eastern Nepal.  Lepr Rev. 200;  71 492-498
    PubMedGoogle Scholar
  • 71 Rao S, Garole V, Walawalkar S et al.. Gender differences in the social impact of leprosy.  Lepr Rev. 1996;  67 190-199
    PubMedGoogle Scholar
  • 72 Peters E S, Eshiet A L. Male-female (sex) differences in leprosy patients in south eastern Nigeria: females present late for diagnosis and treatment and have higher rates of deformity.  Lepr Rev. 2002;  73 262-267
    PubMedGoogle Scholar
  • 73 Arole S, Premkumar R, Arole R, Maury M, Saunderson P. Social stigma: a comparative qualitative study of integrated and vertical care approaches to leprosy.  Lepr Rev. 2002;  73 186-196
    PubMedGoogle Scholar
  • 74 Van Dijk M, Visschedijk J, Van Der Kwaak A. “Client satisfaction”: guidelines for assessing the quality of leprosy services from the clients' perspective.  Lepr Rev. 2003;  74 112-119
    PubMedGoogle Scholar
  • 75 Reichman L B. The U-shaped curve of concern.  Am Rev Respir Dis. 1991;  144 741-742
    PubMedGoogle Scholar

John M GrangeM.Sc. M.D. 

Centre for Infectious Diseases and International Health, Royal Free and University College Medical School, Windeyer Institute for Medical Sciences

46 Cleveland Street, London, W1T 4JF, UK

Email: sophia@hagia.freserve.co.uk

      >